Tricare Continuous Glucose Monitoring for Diagnosis
- Finance
- Watchlists
- My Portfolio
- Cryptocurrencies
- Yahoo Finance Plus
- News
- Screeners
- Markets
- Options: Highest Open Interest
- Options: Highest Implied Volatility
-
- Personal Finance
- Videos
- Influencers with Andy Serwer
- America: Back in Business
-
- All Markets Summit
- Yahoo U
- Industries
- Tech
- Contact Us
-
S&P 500
-
Dow 30
-
Nasdaq
-
Russell 2000
-
Crude Oil
-
Gold
-
Silver
-
EUR/USD
-
10-Yr Bond
-
GBP/USD
-
USD/JPY
-
BTC-USD
-
CMC Crypto 200
-
FTSE 100
-
Nikkei 225
DexCom (DXCM) G6 CGM System Now Available to TRICARE Members
DexCom, Inc. DXCM recently announced that its G6 continuous glucose monitoring ("CGM") System will be available to diabetic military members, their families and retirees as a TRICARE brand-name formulary pharmacy benefit. This will be effective from mid-April 2022 and is expected to provide faster and more convenient access to the Dexcom G6 CGM System to TRICARE members.
With the latest availability to a wider patient pool, DexCom is expected to solidify its foothold in the global CGM business.
A Few Words on Dexcom G6 CGM
Dexcom G6 is equipped with a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device or receiver. This offers patients real-time glucose data without finger pricking. The system also provides customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events and a function that helps patients to share their glucose data in real time with up to 10 followers.
Significance of the Availability
Once effective, diabetic military TRICARE members will be eligible for Dexcom G6 through the military treatment facility pharmacies at zero copayment, the TRICARE retail pharmacy network or through mail order or home delivery. The pharmacy benefit provides a faster process and more consistent copayments for members. Earlier, Dexcom G6 was available via the TRICARE medical benefit by durable medical equipment suppliers where copayment amounts could vary depending on the plan.
Per management, the pharmacy benefit will enable the diabetic TRICARE beneficiaries to utilize the technology to take better and real-time decisions concerning their health, with little to no out-of-pocket costs.
Industry Prospects
Per a report by Grand View Research, the global CGM device market size was valued at $3,929.7 million in 2019 and is expected to reach $10.4 billion by 2027 at a CAGR of 12.7%. Factors like rising cases of diabetes and increasing adoption of CGM devices are likely to drive the market.
Given the market potential, the latest availability is expected to provide a significant boost to DexCom's business globally.
Recent Developments
This month, the company announced that the new Dexcom ONE CGM System will be launched in the United Kingdom in May.
Last month, the company received CE Mark (Conformité Européenne) for the Dexcom G7 CGM System for diabetics in Europe aged two years and above, including pregnant women.
The same month, DexCom announced that effective Mar 14, 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario's Assistive Devices Program for people in the province living with type 1 diabetes above the age of 2 years and meeting coverage criteria.
Price Performance
Shares of the company have gained 24.9% in the past year against the industry's 4.4% fall. The S&P 500 has risen 6.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, DexCom carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Abiomed, Inc. ABMD and Henry Schein, Inc. HSIC.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN's earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
AMN Healthcare has gained 37.3% against the industry's 57.1% fall over the past year.
Abiomed, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 20%. ABMD's earnings surpassed estimates in the trailing four quarters, the average surprise being 9.2%.
Abiomed has lost 9.8% compared with the industry's 4.4% fall over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC's earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 29.7% compared with the industry's 6.2% growth over the past year.
-
77% of Warren Buffett's $313 Billion Portfolio Is Invested in These 6 Stocks
Few high-profile money managers have a nose for making money quite like Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett. In the 57 years since taking the reins, the Oracle of Omaha, as he's come to be known, has led his company's Class A shares (BRK.A) to a jaw-dropping average annual return of 20.1%. The Oracle of Omaha believes diversification is "protection against ignorance."
-
AdGo Green with Green Financing
Building sustainable cities with green financing
-
-
Seeking at Least 9% Dividend Yield? Analysts Suggest 2 Dividend Stocks to Buy
We're facing a storm of volatility, as a series of short rallies have added a layer of confusion on top of the year's bearish trends. The combination of headwinds – high inflation and rising interest rates, a probable recession around the corner – are threatening a stagflation that hasn't been seen since the 1970s. Writing on current conditions from Morgan Stanley, chief US equity strategist Mike Wilson lays out reasons for investor patience, in his forecast of where the main indexes are likely
-
-
Ad12 Foods You Can Eat a Lot of Without Getting Fat
List Of Healthy Foods You Can Eat Without Gaining Any Weight
-
-
Ad30+ Of The Most Amazing Pictures Ever Taken
These captivating photographs capture the unexpected scale of things in the physical world and elsewhere
-
Fidelity's 45% Rule: Should You Really Use It As a Guide to Retirement Savings?
Financial services giant Fidelity has a rule for retirement savings you may have heard of: Have 10 times your annual salary saved for retirement by age 67. This oft-cited guideline can help you identify a retirement savings goal, but it … Continue reading → The post Should the 45% Rule Guide Your Retirement Strategy? appeared first on SmartAsset Blog.
-
Banks forced to hold on to Twitter deal debt-sources
NEW YORK (Reuters) -The banks providing $13 billion in financing for Tesla CEO Elon Musk's acquisition of Twitter Inc have abandoned plans to sell the debt to investors because of uncertainty around the social media company's fortunes and losses, people familiar with the matter said. The banks are not planning to syndicate the debt as is typical with such acquisitions, and are instead planning to keep it on their balance sheets until there is more investor appetite, the sources said. The banks, which include Morgan Stanley, Bank of America, and Barclays Plc, declined to comment.
-
Wall Street Warns of Trouble Brewing in Auto Loans as Prices Dip
(Bloomberg) -- The largest US banks are warning of trouble ahead in auto loans as dropping prices for used cars risk leaving borrowers underwater. Most Read from BloombergSandy Hook Families Ask Judge to Max Out Alex Jones PenaltyTrump Firm's Tax Fraud Trial Promises Ex-CFO as Star WitnessTwitter Tumbles as US Weighs Security Reviews for Musk DealsWells Fargo & Co. said that higher loss rates for loans it originated late last year contributed to an increase in write-offs for the period. Ally Fin
-
AdCost-saving Stone Crusher
50-1000T/H Crushers for Mining, Quarry, Construction. Fixed & Mobile Type. Export to 130+ Countries. 30+ years of Experience, Reliable Quality.
-
AdPuppy Gets Returned For 11th Time Because Of...
Adopting a dog is never a simple procedure as some of the most satisfying pets to own are those that were the most challenging to nurture.
-
Why Shares in Copper Miner Freeport-McMoRan Soared Today
Shares in copper miner Freeport-McMoRan (NYSE: FCX) were up by more than 8% by early afternoon today. The results themselves brought few surprises; after all, investors can see where the price of copper is in the market and therefore ascertain the trend in Freeport's revenue. During the earnings call, CEO Richard Adkerson talked of the physical copper market being "strikingly tight globally right now" and customers "fighting" to get hold of products.
Source: https://finance.yahoo.com/news/dexcom-dxcm-g6-cgm-system-140402865.html
0 Response to "Tricare Continuous Glucose Monitoring for Diagnosis"
Post a Comment